Bros. Advisors Lp Baker Acquires 100,736 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bros. Advisors Lp Baker bought 100,736 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were acquired at an average cost of $7.76 per share, with a total value of $781,711.36. Following the purchase, the insider owned 4,664,924 shares of the company’s stock, valued at $36,199,810.24. The trade was a 2.21% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Tuesday, November 11th, Bros. Advisors Lp Baker purchased 46,434 shares of Entrada Therapeutics stock. The shares were acquired at an average price of $7.50 per share, with a total value of $348,255.00.
• On Monday, November 10th, Bros. Advisors Lp Baker acquired 30,874 shares of Entrada Therapeutics stock. The stock was bought at an average price of $7.21 per share, for a total transaction of $222,601.54.

Entrada Therapeutics Price Performance

NASDAQ TRDA opened at $8.78 on Friday. The stock has a market capitalization of $335.57 million, a P/E ratio of -3.53 and a beta of -0.08. The firm’s 50-day moving average is $6.17 and its two-hundred day moving average is $6.70. Entrada Therapeutics, Inc. has a 12 month low of $4.93 and a 12 month high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.02). Entrada Therapeutics had a negative net margin of 168.16% and a negative return on equity of 26.42%. The company had revenue of $1.61 million during the quarter, compared to analysts’ expectations of $8.62 million. As a group, analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Institutional Investors Weigh In On Entrada Therapeutics

Hedge funds have recently bought and sold shares of the stock. Merck & Co. Inc. purchased a new stake in shares of Entrada Therapeutics in the 1st quarter valued at approximately $15,728,000. Strs Ohio purchased a new position in Entrada Therapeutics in the first quarter valued at $378,000. American Century Companies Inc. raised its stake in Entrada Therapeutics by 13.5% in the first quarter. American Century Companies Inc. now owns 67,793 shares of the company’s stock valued at $613,000 after buying an additional 8,083 shares in the last quarter. Mackenzie Financial Corp lifted its holdings in Entrada Therapeutics by 26.9% during the 1st quarter. Mackenzie Financial Corp now owns 18,396 shares of the company’s stock worth $166,000 after buying an additional 3,896 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of Entrada Therapeutics during the 1st quarter worth about $606,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on TRDA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Entrada Therapeutics in a research note on Wednesday, October 8th. Roth Capital set a $13.00 target price on Entrada Therapeutics in a report on Thursday, November 6th. Wall Street Zen downgraded Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Finally, Zacks Research raised shares of Entrada Therapeutics to a “hold” rating in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Entrada Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $20.67.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.